Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor
cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die. Combining erlotinib with carboplatin
may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining erlotinib and carboplatin in
treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.